drugset / Trial / NCT00676130

Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients

NCT00676130 ↗

Completed 153 enrolled Brigham and Women's Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary aim of this study is to quantify the effectiveness of Bactrim as additional therapy for the treatment of uncomplicated cellulitis in adults, by comparing: standard therapy plus Bactrim, versus standard therapy plus placebo. The primary hypothesis of this study is that, in light of increasing CA-MRSA prevalence, subjects treated with standard therapy plus Bactrim will have higher cure rates than those treated with standard therapy plus placebo.

Timeline

Start
2007-05
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject trimethoprim-sulfamethoxazole Unknown 40 mg —
Subject trimethoprim-sulfamethoxazole Unknown 60 mg —
Subject trimethoprim-sulfamethoxazole Unknown 72 mg —
Subject trimethoprim-sulfamethoxazole Unknown 80 mg —
Subject trimethoprim-sulfamethoxazole Unknown 160 mg —
Background CEPHALEXIN ANHYDROUS Small molecule 300 mg —
Background CEPHALEXIN ANHYDROUS Small molecule 400 mg —
Background CEPHALEXIN ANHYDROUS Small molecule 500 mg —
Background CEPHALEXIN ANHYDROUS Small molecule 1000 mg —

Indications